BG107903A - Изоиндолин-1-он активатори на глюкокиназата - Google Patents

Изоиндолин-1-он активатори на глюкокиназата Download PDF

Info

Publication number: BG107903A
Authority: BG; Bulgaria
Prior art keywords: oxo; cyclohexyl; dihydro; isoindol; propionamide
Prior art date: 2000-12-13

Application number

BG107903A

Other languages

Bulgarian (bg)

English (en)

Inventor

Richard K. Guertin

Original Assignee

F. Hoffmann- La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2003-06-13

Publication date

2004-02-27

2003-06-13 Application filed by F. Hoffmann- La Roche Ag filed Critical F. Hoffmann- La Roche Ag

2004-02-27 Publication of BG107903A publication Critical patent/BG107903A/bg

Links

108010021582 Glucokinase Proteins 0.000 title abstract description 14
102000030595 Glucokinase Human genes 0.000 title abstract description 13
239000012190 activator Substances 0.000 title abstract description 12
PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title abstract description 4
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical class CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims abstract description 16
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 11
-1 benzoimidazolyl Chemical group 0.000 claims description 151
229940080818 propionamide Drugs 0.000 claims description 88
150000001875 compounds Chemical class 0.000 claims description 85
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 48
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
125000001072 heteroaryl group Chemical group 0.000 claims description 36
229910052799 carbon Inorganic materials 0.000 claims description 35
238000002360 preparation method Methods 0.000 claims description 34
150000001721 carbon Chemical group 0.000 claims description 29
125000000217 alkyl group Chemical group 0.000 claims description 28
229910052757 nitrogen Chemical group 0.000 claims description 27
229910052736 halogen Inorganic materials 0.000 claims description 26
150000002367 halogens Chemical group 0.000 claims description 26
238000000034 method Methods 0.000 claims description 23
125000005842 heteroatom Chemical group 0.000 claims description 19
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 17
238000006243 chemical reaction Methods 0.000 claims description 16
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 15
125000004414 alkyl thio group Chemical group 0.000 claims description 14
150000001408 amides Chemical class 0.000 claims description 12
125000002950 monocyclic group Chemical group 0.000 claims description 12
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 11
229910052760 oxygen Inorganic materials 0.000 claims description 11
239000001301 oxygen Chemical group 0.000 claims description 11
125000001424 substituent group Chemical group 0.000 claims description 11
229910052717 sulfur Inorganic materials 0.000 claims description 11
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
125000001309 chloro group Chemical group Cl* 0.000 claims description 9
125000004076 pyridyl group Chemical group 0.000 claims description 9
239000011593 sulfur Substances 0.000 claims description 9
125000000335 thiazolyl group Chemical group 0.000 claims description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
150000001204 N-oxides Chemical class 0.000 claims description 7
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
125000003373 pyrazinyl group Chemical group 0.000 claims description 7
125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
125000001153 fluoro group Chemical group F* 0.000 claims description 6
JFZLHUCEJYRSNM-HNNXBMFYSA-N (2s)-n-(5-chloro-1,3-thiazol-2-yl)-3-cyclohexyl-2-(4-fluoro-3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C([C@H](N1CC=2C=CC=C(C=2C1=O)F)C(=O)NC=1SC(Cl)=CN=1)C1CCCCC1 JFZLHUCEJYRSNM-HNNXBMFYSA-N 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
239000013543 active substance Substances 0.000 claims description 4
125000001246 bromo group Chemical group Br* 0.000 claims description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
MOTYSUWGCCIXCJ-INIZCTEOSA-N (2s)-3-cyclohexyl-2-(4-fluoro-3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@H](N1CC=2C=CC=C(C=2C1=O)F)C(=O)NC=1SC=CN=1)C1CCCCC1 MOTYSUWGCCIXCJ-INIZCTEOSA-N 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
125000005872 benzooxazolyl group Chemical group 0.000 claims description 3
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 3
125000002883 imidazolyl group Chemical group 0.000 claims description 3
NSCIJCDEXRVCMK-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-3-cycloheptyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1C(C2=CC=CC=C2C1)=O)CC1CCCCCC1 NSCIJCDEXRVCMK-UHFFFAOYSA-N 0.000 claims description 3
VPMSFNVPKXVXRA-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-3-cyclopentyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1C(C2=CC=CC=C2C1)=O)CC1CCCC1 VPMSFNVPKXVXRA-UHFFFAOYSA-N 0.000 claims description 3
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
KDUXDFOIUUGGRR-KRWDZBQOSA-N (2s)-3-cyclohexyl-2-(5-nitro-3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@H](N1CC2=CC=C(C=C2C1=O)[N+](=O)[O-])C(=O)NC=1SC=CN=1)C1CCCCC1 KDUXDFOIUUGGRR-KRWDZBQOSA-N 0.000 claims description 2
CLICAWXVUGZAHG-INIZCTEOSA-N (2s)-n-(5-chloro-1,3-thiazol-2-yl)-3-cyclohexyl-2-(6-nitro-3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C([C@H](N1C(=O)C2=CC=C(C=C2C1)[N+](=O)[O-])C(=O)NC=1SC(Cl)=CN=1)C1CCCCC1 CLICAWXVUGZAHG-INIZCTEOSA-N 0.000 claims description 2
XDZPUUOXMDFXIF-IBGZPJMESA-N (2s)-n-(5-chloropyridin-2-yl)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound N1=CC(Cl)=CC=C1NC(=O)[C@@H](N1C(C2=CC=CC=C2C1)=O)CC1CCCCC1 XDZPUUOXMDFXIF-IBGZPJMESA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
201000006747 infectious mononucleosis Diseases 0.000 claims 8
GAHFFZDPDRNMNC-UHFFFAOYSA-N 4-fluoro-2,3-dihydroisoindol-1-one Chemical compound FC1=CC=CC2=C1CNC2=O GAHFFZDPDRNMNC-UHFFFAOYSA-N 0.000 claims 2
CAFYGEUIKNMVSG-SFHVURJKSA-N (2s)-3-cyclohexyl-2-(7-fluoro-3-oxo-1h-isoindol-2-yl)-n-pyrazin-2-ylpropanamide Chemical compound C([C@H](N1C(=O)C=2C=CC=C(C=2C1)F)C(=O)NC=1N=CC=NC=1)C1CCCCC1 CAFYGEUIKNMVSG-SFHVURJKSA-N 0.000 claims 1
LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims 1
125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
SGQYBUJEJYXKCH-UHFFFAOYSA-N n-(1,3-thiazol-2-yl)propanamide Chemical compound CCC(=O)NC1=NC=CS1 SGQYBUJEJYXKCH-UHFFFAOYSA-N 0.000 claims 1
230000003914 insulin secretion Effects 0.000 abstract description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 87
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 84
239000000203 mixture Substances 0.000 description 75
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
239000000243 solution Substances 0.000 description 49
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
230000008878 coupling Effects 0.000 description 35
238000010168 coupling process Methods 0.000 description 35
238000005859 coupling reaction Methods 0.000 description 35
239000003480 eluent Substances 0.000 description 34
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
238000003818 flash chromatography Methods 0.000 description 24
239000002253 acid Substances 0.000 description 23
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
239000007787 solid Substances 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
239000006260 foam Substances 0.000 description 17
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
229910052938 sodium sulfate Inorganic materials 0.000 description 16
235000011152 sodium sulphate Nutrition 0.000 description 16
GEKUFTBQNVFPHS-HNNXBMFYSA-N (2s)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=CC=CC=C2C1)=O)C1CCCCC1 GEKUFTBQNVFPHS-HNNXBMFYSA-N 0.000 description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 14
239000000284 extract Substances 0.000 description 14
239000008103 glucose Substances 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
239000011734 sodium Substances 0.000 description 12
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000012267 brine Substances 0.000 description 10
150000002148 esters Chemical class 0.000 description 10
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 10
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
239000012043 crude product Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
239000008280 blood Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 6
GTMGFQYVLSQTKP-UHFFFAOYSA-N 5-chloro-1,3-thiazol-3-ium-2-amine;chloride Chemical compound Cl.NC1=NC=C(Cl)S1 GTMGFQYVLSQTKP-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
239000002585 base Substances 0.000 description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
239000010410 layer Substances 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
239000000047 product Substances 0.000 description 6
HAZJQNXTVYBGMP-KRWDZBQOSA-N (2s)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound O=C([C@H](CC1CCCCC1)N1C(C2=CC=CC=C2C1)=O)NC1=NC=CS1 HAZJQNXTVYBGMP-KRWDZBQOSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
229910052786 argon Inorganic materials 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
238000010992 reflux Methods 0.000 description 5
238000004007 reversed phase HPLC Methods 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
OWKBKSGHGBDMNC-HNNXBMFYSA-N (2s)-3-cyclohexyl-2-(6-nitro-3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=CC=C(C=C2C1)[N+]([O-])=O)=O)C1CCCCC1 OWKBKSGHGBDMNC-HNNXBMFYSA-N 0.000 description 4
RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241000271317 Gonystylus bancanus Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
230000004153 glucose metabolism Effects 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
150000003222 pyridines Chemical class 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
WSJGMGPBDAOSKR-HNNXBMFYSA-N (2s)-3-cyclohexyl-2-(7-fluoro-3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=C(C(=CC=C2)F)C1)=O)C1CCCCC1 WSJGMGPBDAOSKR-HNNXBMFYSA-N 0.000 description 3
JTYBTJVFXUKNKW-UHFFFAOYSA-N 2-(2,4,5-trifluorophenyl)acetonitrile Chemical compound FC1=CC(F)=C(CC#N)C=C1F JTYBTJVFXUKNKW-UHFFFAOYSA-N 0.000 description 3
YXOAUUWLNQFGOQ-UHFFFAOYSA-N 3-cyclopentyl-2-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(C(=O)O)CC1CCCC1 YXOAUUWLNQFGOQ-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000005548 Hexokinase Human genes 0.000 description 3
108700040460 Hexokinases Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
BVWREOCJVMLGTJ-UHFFFAOYSA-N [2-(hydroxymethyl)-4-nitrophenyl]methanol Chemical compound OCC1=CC=C([N+]([O-])=O)C=C1CO BVWREOCJVMLGTJ-UHFFFAOYSA-N 0.000 description 3
NDQYVFKHPRRCSL-UHFFFAOYSA-N [3-chloro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC(Cl)=C1CO NDQYVFKHPRRCSL-UHFFFAOYSA-N 0.000 description 3
UAXMLIVNXZKEOV-UHFFFAOYSA-N [3-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC(F)=C1CO UAXMLIVNXZKEOV-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
229940099112 cornstarch Drugs 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
CHGPELMANYOUNH-UHFFFAOYSA-N dimethyl 3-fluorobenzene-1,2-dicarboxylate Chemical compound COC(=O)C1=CC=CC(F)=C1C(=O)OC CHGPELMANYOUNH-UHFFFAOYSA-N 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
229940045189 glucose-6-phosphate Drugs 0.000 description 3
102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 3
108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000011630 iodine Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 3
235000019260 propionic acid Nutrition 0.000 description 3
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
238000000926 separation method Methods 0.000 description 3
GEKUFTBQNVFPHS-OAHLLOKOSA-N (2r)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C([C@H](C(=O)O)N1C(C2=CC=CC=C2C1)=O)C1CCCCC1 GEKUFTBQNVFPHS-OAHLLOKOSA-N 0.000 description 2
FOBTWFHCMITRKD-HNNXBMFYSA-N (2s)-2-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-(5-chloro-1,3-thiazol-2-yl)-3-cyclohexylpropanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@@H](N1C(C2=C(Cl)C=CC=C2C1)=O)CC1CCCCC1 FOBTWFHCMITRKD-HNNXBMFYSA-N 0.000 description 2
LCUKXLCZLIIJLV-HNNXBMFYSA-N (2s)-2-(7-chloro-3-oxo-1h-isoindol-2-yl)-3-cyclohexylpropanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=C(C(=CC=C2)Cl)C1)=O)C1CCCCC1 LCUKXLCZLIIJLV-HNNXBMFYSA-N 0.000 description 2
VFFPWUGCWCCOLR-INIZCTEOSA-N (2s)-2-(7-chloro-3-oxo-1h-isoindol-2-yl)-n-(5-chloro-1,3-thiazol-2-yl)-3-cyclohexylpropanamide Chemical compound S1C(Cl)=CN=C1NC(=O)[C@@H](N1C(C2=C(C(=CC=C2)Cl)C1)=O)CC1CCCCC1 VFFPWUGCWCCOLR-INIZCTEOSA-N 0.000 description 2
CZPDANYBRUJHEO-HNNXBMFYSA-N (2s)-3-cyclohexyl-2-(5,6-dichloro-3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=CC(Cl)=C(Cl)C=C2C1)=O)C1CCCCC1 CZPDANYBRUJHEO-HNNXBMFYSA-N 0.000 description 2
GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 2
KTPMVZCGIJJWCD-UHFFFAOYSA-N 1-hydroxypyridin-2-imine Chemical compound ON1C=CC=CC1=N KTPMVZCGIJJWCD-UHFFFAOYSA-N 0.000 description 2
DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical compound NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
PSYRORCNCYQOIA-UHFFFAOYSA-N 2-amino-3-cyclooctylpropanoic acid Chemical compound OC(=O)C(N)CC1CCCCCCC1 PSYRORCNCYQOIA-UHFFFAOYSA-N 0.000 description 2
BKFXSOCDAQACQM-UHFFFAOYSA-N 3-chlorophthalic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1C(O)=O BKFXSOCDAQACQM-UHFFFAOYSA-N 0.000 description 2
CRJFRTOZGDAQPG-UHFFFAOYSA-N 3-cycloheptyl-2-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1CCCCCC1CC(N1C(C2=CC=CC=C2C1)=O)C(=O)NC1=NC=CS1 CRJFRTOZGDAQPG-UHFFFAOYSA-N 0.000 description 2
BBCQSMSCEJBIRD-UHFFFAOYSA-N 3-fluorophthalic acid Chemical compound OC(=O)C1=CC=CC(F)=C1C(O)=O BBCQSMSCEJBIRD-UHFFFAOYSA-N 0.000 description 2
239000004342 Benzoyl peroxide Substances 0.000 description 2
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
VZFUCHSFHOYXIS-UHFFFAOYSA-N Cycloheptanecarboxylic acid Chemical compound OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 2
101150109586 Gk gene Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
WSCRUXVCUXHCOW-UHFFFAOYSA-N [4,5-dichloro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC(Cl)=C(Cl)C=C1CO WSCRUXVCUXHCOW-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000011260 aqueous acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
235000019400 benzoyl peroxide Nutrition 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
BMCQFFXPECPDPS-UHFFFAOYSA-N cycloheptylmethanol Chemical compound OCC1CCCCCC1 BMCQFFXPECPDPS-UHFFFAOYSA-N 0.000 description 2
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
229940079593 drug Drugs 0.000 description 2
125000001033 ether group Chemical group 0.000 description 2
239000003925 fat Substances 0.000 description 2
230000014101 glucose homeostasis Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
REEPTAINTWFSIK-UHFFFAOYSA-N iodomethylcyclooctane Chemical compound ICC1CCCCCCC1 REEPTAINTWFSIK-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
QJCZYKAVUAOAOA-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-3-cyclohexyl-2-(5,6-dichloro-3-oxo-1h-isoindol-2-yl)propanamide Chemical compound O=C1C=2C=C(Cl)C(Cl)=CC=2CN1C(C(=O)NC=1SC(Br)=CN=1)CC1CCCCC1 QJCZYKAVUAOAOA-UHFFFAOYSA-N 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
WAPJVSYAZYVYAB-UHFFFAOYSA-N tert-butyl 2-(benzhydrylideneamino)-3-cycloheptylpropanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)=NC(C(=O)OC(C)(C)C)CC1CCCCCC1 WAPJVSYAZYVYAB-UHFFFAOYSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
150000003557 thiazoles Chemical class 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
HAZJQNXTVYBGMP-QGZVFWFLSA-N (2r)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound O=C([C@@H](CC1CCCCC1)N1C(C2=CC=CC=C2C1)=O)NC1=NC=CS1 HAZJQNXTVYBGMP-QGZVFWFLSA-N 0.000 description 1
AVZFDRVTBXTFED-LJQANCHMSA-N (2r)-n-(5-bromopyridin-2-yl)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound N1=CC(Br)=CC=C1NC(=O)[C@H](N1C(C2=CC=CC=C2C1)=O)CC1CCCCC1 AVZFDRVTBXTFED-LJQANCHMSA-N 0.000 description 1
NOHJJASTBHVIBA-KRWDZBQOSA-N (2s)-2-(4-chloro-3-oxo-1h-isoindol-2-yl)-3-cyclohexyl-n-pyrazin-2-ylpropanamide Chemical compound C([C@H](N1CC=2C=CC=C(C=2C1=O)Cl)C(=O)NC=1N=CC=NC=1)C1CCCCC1 NOHJJASTBHVIBA-KRWDZBQOSA-N 0.000 description 1
IMQABFYLCVJPJC-SFHVURJKSA-N (2s)-2-(4-chloro-3-oxo-1h-isoindol-2-yl)-3-cyclohexyl-n-pyridin-2-ylpropanamide Chemical compound C([C@H](N1CC=2C=CC=C(C=2C1=O)Cl)C(=O)NC=1N=CC=CC=1)C1CCCCC1 IMQABFYLCVJPJC-SFHVURJKSA-N 0.000 description 1
AHVCMOLBTSFGKY-AWEZNQCLSA-N (2s)-2-(4-chloro-3-oxo-1h-isoindol-2-yl)-3-cyclohexylpropanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=C(Cl)C=CC=C2C1)=O)C1CCCCC1 AHVCMOLBTSFGKY-AWEZNQCLSA-N 0.000 description 1
BMJGFYCEVPVPNV-KRWDZBQOSA-N (2s)-2-(7-chloro-3-oxo-1h-isoindol-2-yl)-3-cyclohexyl-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@H](N1C(=O)C=2C=CC=C(C=2C1)Cl)C(=O)NC=1SC=CN=1)C1CCCCC1 BMJGFYCEVPVPNV-KRWDZBQOSA-N 0.000 description 1
ADKARQQIMWDUGM-IBGZPJMESA-N (2s)-2-(7-chloro-3-oxo-1h-isoindol-2-yl)-3-cyclohexyl-n-pyridin-2-ylpropanamide Chemical compound C([C@H](N1C(=O)C=2C=CC=C(C=2C1)Cl)C(=O)NC=1N=CC=CC=1)C1CCCCC1 ADKARQQIMWDUGM-IBGZPJMESA-N 0.000 description 1
VIPWGMMDZOTSGY-IBGZPJMESA-N (2s)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound O=C([C@H](CC1CCCCC1)N1C(C2=CC=CC=C2C1)=O)NC1=CC=CC=N1 VIPWGMMDZOTSGY-IBGZPJMESA-N 0.000 description 1
VEMZDALOYZQAEW-QHCPKHFHSA-N (2s)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)-n-quinolin-2-ylpropanamide Chemical compound C([C@@H](C(NC=1N=C2C=CC=CC2=CC=1)=O)N1C(C2=CC=CC=C2C1)=O)C1CCCCC1 VEMZDALOYZQAEW-QHCPKHFHSA-N 0.000 description 1
LHNQWIYWCFTZSJ-AWEZNQCLSA-N (2s)-3-cyclohexyl-2-(4-fluoro-3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=C(F)C=CC=C2C1)=O)C1CCCCC1 LHNQWIYWCFTZSJ-AWEZNQCLSA-N 0.000 description 1
PQWVLWHMNCYCSN-HNNXBMFYSA-N (2s)-3-cyclohexyl-2-(5-nitro-3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1C(C2=CC(=CC=C2C1)[N+]([O-])=O)=O)C1CCCCC1 PQWVLWHMNCYCSN-HNNXBMFYSA-N 0.000 description 1
FSHQEAUMFQXYOM-SFHVURJKSA-N (2s)-3-cyclohexyl-2-(7-methylsulfonyl-3-oxo-1h-isoindol-2-yl)-n-pyrazin-2-ylpropanamide Chemical compound C([C@H](N1C(=O)C=2C=CC=C(C=2C1)S(=O)(=O)C)C(=O)NC=1N=CC=NC=1)C1CCCCC1 FSHQEAUMFQXYOM-SFHVURJKSA-N 0.000 description 1
RXKUQKUECLOWDJ-KRWDZBQOSA-N (2s)-3-cyclohexyl-n-(1h-imidazol-2-yl)-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound O=C([C@H](CC1CCCCC1)N1C(C2=CC=CC=C2C1)=O)NC1=NC=CN1 RXKUQKUECLOWDJ-KRWDZBQOSA-N 0.000 description 1
HEMJGYNZNHUXMQ-FQEVSTJZSA-N (2s)-n-(1,3-benzoxazol-2-yl)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C([C@@H](C(NC=1OC2=CC=CC=C2N=1)=O)N1C(C2=CC=CC=C2C1)=O)C1CCCCC1 HEMJGYNZNHUXMQ-FQEVSTJZSA-N 0.000 description 1
JRASWERIVQXADO-NRFANRHFSA-N (2s)-n-(1h-benzimidazol-2-yl)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C([C@@H](C(NC=1NC2=CC=CC=C2N=1)=O)N1C(C2=CC=CC=C2C1)=O)C1CCCCC1 JRASWERIVQXADO-NRFANRHFSA-N 0.000 description 1
MVWXBJNCJHLRBQ-INIZCTEOSA-N (2s)-n-(5-chloro-1,3-thiazol-2-yl)-3-cyclohexyl-2-(7-fluoro-3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C([C@H](N1C(=O)C=2C=CC=C(C=2C1)F)C(=O)NC=1SC(Cl)=CN=1)C1CCCCC1 MVWXBJNCJHLRBQ-INIZCTEOSA-N 0.000 description 1
PLENEAJJYFHWBP-HNNXBMFYSA-N (2s)-n-cyclohexyl-n-(2-methylpyrimidin-4-yl)-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound O=C([C@@H](N1C(C2=CC=CC=C2C1)=O)C)N(C=1N=C(C)N=CC=1)C1CCCCC1 PLENEAJJYFHWBP-HNNXBMFYSA-N 0.000 description 1
125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
AVGQTJUPLKNPQP-UHFFFAOYSA-N 1,1,1-trichloropropane Chemical compound CCC(Cl)(Cl)Cl AVGQTJUPLKNPQP-UHFFFAOYSA-N 0.000 description 1
JPBLHOJFMBOCAF-UHFFFAOYSA-N 1,3-benzoxazol-2-amine Chemical compound C1=CC=C2OC(N)=NC2=C1 JPBLHOJFMBOCAF-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
UWCWUCKPEYNDNV-LBPRGKRZSA-N 2,6-dimethyl-n-[[(2s)-pyrrolidin-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C)=C1NC[C@H]1NCCC1 UWCWUCKPEYNDNV-LBPRGKRZSA-N 0.000 description 1
OZKCCMYHACYIMI-UHFFFAOYSA-N 2-(1,3-thiazol-4-yl)propanamide Chemical compound NC(=O)C(C)C1=CSC=N1 OZKCCMYHACYIMI-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
GHCFWKFREBNSPC-UHFFFAOYSA-N 2-Amino-4-methylpyrimidine Chemical compound CC1=CC=NC(N)=N1 GHCFWKFREBNSPC-UHFFFAOYSA-N 0.000 description 1
ZLOCOQNMVGDMBT-UHFFFAOYSA-N 2-[(5,6-dihydroxy-4-methoxy-2h-pyran-2-yl)oxy]-4-methoxy-2h-pyran-5,6-diol Chemical class O1C(O)=C(O)C(OC)=CC1OC1C=C(OC)C(O)=C(O)O1 ZLOCOQNMVGDMBT-UHFFFAOYSA-N 0.000 description 1
JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
KDYAKYRBGLKMAK-UHFFFAOYSA-N 2-azaniumyl-3-cyclopentylpropanoate Chemical compound OC(=O)C(N)CC1CCCC1 KDYAKYRBGLKMAK-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
XUMNTSBMYFJMQY-UHFFFAOYSA-N 3-cycloheptyl-2-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(C(=O)O)CC1CCCCCC1 XUMNTSBMYFJMQY-UHFFFAOYSA-N 0.000 description 1
HAZJQNXTVYBGMP-UHFFFAOYSA-N 3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1CCCCC1CC(N1C(C2=CC=CC=C2C1)=O)C(=O)NC1=NC=CS1 HAZJQNXTVYBGMP-UHFFFAOYSA-N 0.000 description 1
MCSTZKDFCAKYAJ-UHFFFAOYSA-N 3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)-n-pyrimidin-4-ylpropanamide Chemical compound C1CCCCC1CC(N1C(C2=CC=CC=C2C1)=O)C(=O)NC1=CC=NC=N1 MCSTZKDFCAKYAJ-UHFFFAOYSA-N 0.000 description 1
PWPUNWJDAFANEV-UHFFFAOYSA-N 3-cyclopentyl-2-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1CCCC1CC(N1C(C2=CC=CC=C2C1)=O)C(=O)NC1=NC=CS1 PWPUNWJDAFANEV-UHFFFAOYSA-N 0.000 description 1
FDOQKGWUMUEJLX-UHFFFAOYSA-N 4,5-dichlorophthalic acid Chemical compound OC(=O)C1=CC(Cl)=C(Cl)C=C1C(O)=O FDOQKGWUMUEJLX-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
SLBQXWXKPNIVSQ-UHFFFAOYSA-N 4-nitrophthalic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1C(O)=O SLBQXWXKPNIVSQ-UHFFFAOYSA-N 0.000 description 1
XFDCNXIWKCIBAE-UHFFFAOYSA-N 5-bromo-1,3-thiazol-2-amine;hydrochloride Chemical compound Cl.NC1=NC=C(Br)S1 XFDCNXIWKCIBAE-UHFFFAOYSA-N 0.000 description 1
WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 description 1
CMBSSVKZOPZBKW-UHFFFAOYSA-N 5-methylpyridin-2-amine Chemical compound CC1=CC=C(N)N=C1 CMBSSVKZOPZBKW-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
UZIBAYILDWDNRR-JGHKVMFLSA-N C1(CCCCC1)C=1C(NC=CC1)(N1C(C2=CC=CC=C2C1)=O)[C@@H](C(=O)N)C Chemical compound C1(CCCCC1)C=1C(NC=CC1)(N1C(C2=CC=CC=C2C1)=O)[C@@H](C(=O)N)C UZIBAYILDWDNRR-JGHKVMFLSA-N 0.000 description 1
JDAKJRTUUJGQGD-WMISSQJSSA-N C1(CCCCC1)C[C@@H](C(=O)O)N1C(C2=CC=CC(=C2C1)Cl)=O.C1(CCCCC1)C[C@@H](C(=O)O)N1C(C2=C(C=CC=C2C1)Cl)=O Chemical compound C1(CCCCC1)C[C@@H](C(=O)O)N1C(C2=CC=CC(=C2C1)Cl)=O.C1(CCCCC1)C[C@@H](C(=O)O)N1C(C2=C(C=CC=C2C1)Cl)=O JDAKJRTUUJGQGD-WMISSQJSSA-N 0.000 description 1
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
JUFSZQFRNHWIEO-UHFFFAOYSA-N CS(=O)(=O)C=1C=CC=C2CN(C(C12)=O)C(C(=O)O)C Chemical compound CS(=O)(=O)C=1C=CC=C2CN(C(C12)=O)C(C(=O)O)C JUFSZQFRNHWIEO-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
GACTWZZMVMUKNG-UHFFFAOYSA-N D-sorbitol phosphate Natural products OCC(O)C(O)C(O)C(O)COP(O)(O)=O GACTWZZMVMUKNG-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102100023903 Glycerol kinase Human genes 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
241000192130 Leuconostoc mesenteroides Species 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
XMUZQOKACOLCSS-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC=C1CO XMUZQOKACOLCSS-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001262 acyl bromides Chemical class 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
125000005103 alkyl silyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
229950011175 aminopicoline Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 description 1
PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000036765 blood level Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229950005499 carbon tetrachloride Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical class ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
UPEPJKHYMZVGQV-UHFFFAOYSA-N cycloheptane;methane Chemical compound C.C1CCCCCC1 UPEPJKHYMZVGQV-UHFFFAOYSA-N 0.000 description 1
ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical group COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
DBEYVIGIPJSTOR-FHWLQOOXSA-N fumitremorgin C Chemical compound O=C1[C@@H]2CCCN2C(=O)[C@@H]2CC(C3=CC=C(C=C3N3)OC)=C3[C@H](C=C(C)C)N21 DBEYVIGIPJSTOR-FHWLQOOXSA-N 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940124828 glucokinase activator Drugs 0.000 description 1
230000009229 glucose formation Effects 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910001510 metal chloride Inorganic materials 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
230000035772 mutation Effects 0.000 description 1
JKHHPJPIEXQNBA-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound N=1C2=CC=CC=C2SC=1NC(=O)C(N1C(C2=CC=CC=C2C1)=O)CC1CCCCC1 JKHHPJPIEXQNBA-UHFFFAOYSA-N 0.000 description 1
JRASWERIVQXADO-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound N=1C2=CC=CC=C2NC=1NC(=O)C(N1C(C2=CC=CC=C2C1)=O)CC1CCCCC1 JRASWERIVQXADO-UHFFFAOYSA-N 0.000 description 1
UYCVBXJBAQSWQH-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-3-cyclohexyl-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound S1C(Br)=CN=C1NC(=O)C(N1C(C2=CC=CC=C2C1)=O)CC1CCCCC1 UYCVBXJBAQSWQH-UHFFFAOYSA-N 0.000 description 1
UCWQHVABVFGEJB-UHFFFAOYSA-N n-pyrazin-2-ylpropanamide Chemical compound CCC(=O)NC1=CN=CC=N1 UCWQHVABVFGEJB-UHFFFAOYSA-N 0.000 description 1
QAXHWMWOMJZFCA-UHFFFAOYSA-N n-quinolin-2-ylpropanamide Chemical compound C1=CC=CC2=NC(NC(=O)CC)=CC=C21 QAXHWMWOMJZFCA-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003216 pyrazines Chemical class 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
230000006340 racemization Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
IPMKAUAKEGAJNA-XSUJLISDSA-N solanapyrone g Chemical compound C1([C@H]2[C@@H]3CCCC[C@@H]3C=C[C@@H]2C)=CC(N)=C(C=O)C(=O)O1 IPMKAUAKEGAJNA-XSUJLISDSA-N 0.000 description 1
GACTWZZMVMUKNG-ZXXMMSQZSA-N sorbitol 6-phosphate Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)COP(O)(O)=O GACTWZZMVMUKNG-ZXXMMSQZSA-N 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
YSHDPXQDVKNPKA-UHFFFAOYSA-N tert-butyl 2-(benzhydrylideneamino)acetate Chemical compound C=1C=CC=CC=1C(=NCC(=O)OC(C)(C)C)C1=CC=CC=C1 YSHDPXQDVKNPKA-UHFFFAOYSA-N 0.000 description 1
XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
125000004954 trialkylamino group Chemical group 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

BG107903A 2000-12-13 2003-06-13 Изоиндолин-1-он активатори на глюкокиназата BG107903A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25527300P	2000-12-13	2000-12-13
US31871501P	2001-09-13	2001-09-13
PCT/EP2001/014404 WO2002048106A2 (fr)	2000-12-13	2001-12-07	Activateurs de l'isoindoline-1-one glucokinase

Publications (1)

Publication Number	Publication Date
BG107903A true BG107903A (bg)	2004-02-27

Family

ID=26944583

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107903A BG107903A (bg)	2000-12-13	2003-06-13	Изоиндолин-1-он активатори на глюкокиназата

Country Status (35)

Country	Link
US (1)	US6482951B2 (fr)
EP (1)	EP1349856B1 (fr)
JP (1)	JP4021766B2 (fr)
KR (1)	KR100520651B1 (fr)
CN (1)	CN1247574C (fr)
AT (1)	ATE297922T1 (fr)
AU (2)	AU3841502A (fr)
BG (1)	BG107903A (fr)
BR (1)	BR0116169A (fr)
CA (1)	CA2430579C (fr)
CY (1)	CY1105587T1 (fr)
CZ (1)	CZ20031882A3 (fr)
DE (1)	DE60111570T2 (fr)
DK (1)	DK1349856T3 (fr)
EG (1)	EG24358A (fr)
ES (1)	ES2243578T3 (fr)
HR (1)	HRP20030450B1 (fr)
HU (1)	HUP0400587A3 (fr)
IL (2)	IL156264A0 (fr)
MA (1)	MA26973A1 (fr)
MX (1)	MXPA03005170A (fr)
MY (1)	MY136741A (fr)
NO (1)	NO325810B1 (fr)
NZ (1)	NZ526236A (fr)
PA (1)	PA8534601A1 (fr)
PE (1)	PE20020593A1 (fr)
PL (1)	PL366006A1 (fr)
PT (1)	PT1349856E (fr)
RS (1)	RS50933B (fr)
RU (1)	RU2249590C2 (fr)
SI (1)	SI1349856T1 (fr)
SK (1)	SK8732003A3 (fr)
TW (1)	TWI294876B (fr)
UY (1)	UY27069A1 (fr)
WO (1)	WO2002048106A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0102299D0 (sv)	2001-06-26	2001-06-26	Astrazeneca Ab	Compounds
SE0102764D0 (sv)	2001-08-17	2001-08-17	Astrazeneca Ab	Compounds
MXPA05003559A (es)	2002-10-03	2005-06-03	Novartis Ag	(tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2.
PT1549638E (pt)	2002-10-03	2007-12-11	Hoffmann La Roche	Indole-3-cabboxamidas como activantes da glucoquinase
GB0226931D0 (en)	2002-11-19	2002-12-24	Astrazeneca Ab	Chemical compounds
WO2004063194A1 (fr) *	2003-01-06	2004-07-29	Eli Lilly And Company	Composes heteroaryle
PL378117A1 (pl) *	2003-02-11	2006-03-06	Prosidion Limited	Tricyklopodstawione związki amidowe
EP1594863A1 (fr) *	2003-02-11	2005-11-16	Prosidion Limited	Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
US7320992B2 (en) *	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
AU2005229416B2 (en)	2004-04-02	2009-03-26	Novartis Ag	Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
KR20070006816A (ko) *	2004-04-02	2007-01-11	노파르티스 아게	티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
NZ564608A (en)	2005-07-09	2009-09-25	Astrazeneca Ab	Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP1921074A1 (fr) *	2005-08-31	2008-05-14	Astellas Pharma Inc.	Dérivé de thiazole
JP2007063225A (ja) *	2005-09-01	2007-03-15	Takeda Chem Ind Ltd	イミダゾピリジン化合物
CA2624102A1 (fr)	2005-09-29	2007-04-12	Sanofi-Aventis	Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
GT200600428A (es) *	2005-09-30	2007-05-21		Compuestos organicos
GT200600429A (es) *	2005-09-30	2007-04-30		Compuestos organicos
US8796313B2 (en)	2005-11-01	2014-08-05	Janssen Pharmaceutica N.V.	Substituted dihydroisoindolones as allosteric modulators of glucokinase
WO2007053765A2 (fr) *	2005-11-01	2007-05-10	Janssen Pharmaceutica N.V.	Cycloalkylpyrrolones substitues utilises en tant que modulateurs allosteriques de glucokinase
WO2007053662A1 (fr) *	2005-11-01	2007-05-10	Janssen Pharmaceutica N.V.	Dihydroisoindolones utilisées comme modulateurs allostériques de la glucokinase
CA2627813A1 (fr) *	2005-11-01	2007-05-10	Janssen Pharmaceutica N.V.	Pyrrolones substitues utilises en tant que modulateurs allosteriques de glucokinase
JP2009514835A (ja) *	2005-11-03	2009-04-09	プロシディオン・リミテッド	トリシクロ置換型アミド
US20070197532A1 (en) *	2005-11-18	2007-08-23	Cao Sheldon X	Glucokinase activators
US8034822B2 (en)	2006-03-08	2011-10-11	Takeda San Diego, Inc.	Glucokinase activators
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
JP5386350B2 (ja) *	2006-05-31	2014-01-15	タケダカリフォルニアインコーポレイテッド	グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
JP5419706B2 (ja) *	2006-12-20	2014-02-19	タケダカリフォルニアインコーポレイテッド	グルコキナーゼアクチベーター
WO2008074694A1 (fr) *	2006-12-20	2008-06-26	F. Hoffmann-La Roche Ag	Cristallisation d'activateurs de glucokinase
TW200831081A (en) *	2006-12-25	2008-08-01	Kyorin Seiyaku Kk	Glucokinase activator
MX2009009525A (es) *	2007-03-07	2009-09-16	Kyorin Seiyaku Kk	Activador de glucocinasa.
WO2008116107A2 (fr) *	2007-03-21	2008-09-25	Takeda San Diego, Inc.	Activateurs de glucokinase
TW200934772A (en) *	2008-01-15	2009-08-16	Lilly Co Eli	Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
KR20100110367A (ko) *	2008-01-24	2010-10-12	메르크 파텐트 게엠베하	당뇨병 치료를 위한 베타-아미노산 유도체들
HRP20150842T1 (hr) *	2008-04-28	2015-09-11	Kyorin Pharmaceutical Co., Ltd.	Derivati ciklopentilakrilamida
EA018988B1 (ru)	2008-05-16	2013-12-30	Такеда Калифорния, Инк.	Активаторы глюкокиназы
PE20110303A1 (es) *	2008-09-11	2011-05-21	Pfizer	Derivados de heteroaril acetamidas como activadores de glucoquinasa
EP2553086B1 (fr)	2010-03-31	2017-04-19	The Scripps Research Institute	Nouvelle programmation de cellules
US8178689B2 (en) *	2010-06-17	2012-05-15	Hoffman-La Roche Inc.	Tricyclic compounds
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (fr)	2011-03-01	2024-03-05	Synergy Pharmaceuticals Inc.	Procede de preparation d'agonistes du guanylate cyclase c
US8470866B2 (en) *	2011-05-03	2013-06-25	Hoffmann-La Roche Inc.	Isoindolinone derivatives
RU2693698C2 (ru) *	2013-05-27	2019-07-04	Ф. Хоффманн-Ля Рош Аг	Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она
EA201592263A1 (ru)	2013-06-05	2016-05-31	Синерджи Фармасьютикалз, Инк.	Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
EP3186242B1 (fr)	2014-08-29	2021-10-06	Tes Pharma S.r.l.	Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN116283717B (zh) *	2023-01-06	2025-04-08	暨南大学	一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (fr) *	2023-05-02	2024-11-07	The Rockefeller University	Activateurs de 1-oxoisoindoline-2-yl amide de vcp et leurs dérivés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2687147A1 (fr) *	1992-02-11	1993-08-13	Union Pharma Scient Appl	Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
JP3314938B2 (ja) *	1995-06-06	2002-08-19	ファイザー・インコーポレーテッド	グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
CZ301366B6 (cs)	1999-03-29	2010-02-03	F. Hoffmann-La Roche Ag	2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
AU5227001A (en)	2000-05-03	2001-11-12	Hoffmann La Roche	Hydantoin-containing glucokinase activators
EP1282611B1 (fr)	2000-05-08	2004-10-20	F. Hoffmann-La Roche Ag	Phenylacetamides substitues et leur utilisation en tant qu'activateurs de la glucokinase

2001
- 2001-12-06 US US10/010,978 patent/US6482951B2/en not_active Expired - Fee Related
- 2001-12-07 RS YUP-477/03A patent/RS50933B/sr unknown
- 2001-12-07 RU RU2003120512/04A patent/RU2249590C2/ru not_active IP Right Cessation
- 2001-12-07 CN CNB018206107A patent/CN1247574C/zh not_active Expired - Fee Related
- 2001-12-07 MX MXPA03005170A patent/MXPA03005170A/es active IP Right Grant
- 2001-12-07 NZ NZ526236A patent/NZ526236A/xx unknown
- 2001-12-07 KR KR10-2003-7007869A patent/KR100520651B1/ko not_active Expired - Fee Related
- 2001-12-07 CZ CZ20031882A patent/CZ20031882A3/cs unknown
- 2001-12-07 PL PL01366006A patent/PL366006A1/xx unknown
- 2001-12-07 ES ES01986857T patent/ES2243578T3/es not_active Expired - Lifetime
- 2001-12-07 JP JP2002549637A patent/JP4021766B2/ja not_active Expired - Fee Related
- 2001-12-07 AU AU3841502A patent/AU3841502A/xx active Pending
- 2001-12-07 HU HU0400587A patent/HUP0400587A3/hu unknown
- 2001-12-07 EP EP01986857A patent/EP1349856B1/fr not_active Expired - Lifetime
- 2001-12-07 CA CA2430579A patent/CA2430579C/fr not_active Expired - Fee Related
- 2001-12-07 PT PT01986857T patent/PT1349856E/pt unknown
- 2001-12-07 IL IL15626401A patent/IL156264A0/xx unknown
- 2001-12-07 AT AT01986857T patent/ATE297922T1/de active
- 2001-12-07 SI SI200130381T patent/SI1349856T1/xx unknown
- 2001-12-07 BR BR0116169-5A patent/BR0116169A/pt not_active Application Discontinuation
- 2001-12-07 DE DE60111570T patent/DE60111570T2/de not_active Expired - Lifetime
- 2001-12-07 SK SK873-2003A patent/SK8732003A3/sk unknown
- 2001-12-07 AU AU2002238415A patent/AU2002238415B2/en not_active Ceased
- 2001-12-07 HR HR20030450A patent/HRP20030450B1/xx not_active IP Right Cessation
- 2001-12-07 WO PCT/EP2001/014404 patent/WO2002048106A2/fr not_active Ceased
- 2001-12-07 DK DK01986857T patent/DK1349856T3/da active
- 2001-12-10 EG EG20011316A patent/EG24358A/xx active
- 2001-12-10 TW TW090130510A patent/TWI294876B/zh not_active IP Right Cessation
- 2001-12-10 PA PA20018534601A patent/PA8534601A1/es unknown
- 2001-12-11 PE PE2001001234A patent/PE20020593A1/es not_active Application Discontinuation
- 2001-12-11 MY MYPI20015613A patent/MY136741A/en unknown
- 2001-12-12 UY UY27069A patent/UY27069A1/es not_active Application Discontinuation
2003
- 2003-06-02 IL IL156264A patent/IL156264A/en not_active IP Right Cessation
- 2003-06-12 MA MA27197A patent/MA26973A1/fr unknown
- 2003-06-12 NO NO20032674A patent/NO325810B1/no not_active IP Right Cessation
- 2003-06-13 BG BG107903A patent/BG107903A/bg unknown
2005
- 2005-09-15 CY CY20051101133T patent/CY1105587T1/el unknown

Also Published As

Publication number	Publication date
IL156264A (en)	2010-11-30
CA2430579C (fr)	2010-01-26
RU2249590C2 (ru)	2005-04-10
HUP0400587A3 (en)	2011-03-28
PA8534601A1 (es)	2002-08-26
US20020082260A1 (en)	2002-06-27
HRP20030450A2 (en)	2005-04-30
BR0116169A (pt)	2003-12-23
HRP20030450B1 (en)	2006-02-28
WO2002048106A3 (fr)	2002-11-28
WO2002048106A2 (fr)	2002-06-20
PE20020593A1 (es)	2002-07-06
EP1349856A2 (fr)	2003-10-08
AU3841502A (en)	2002-06-24
KR20030064817A (ko)	2003-08-02
EP1349856B1 (fr)	2005-06-15
PT1349856E (pt)	2005-09-30
CA2430579A1 (fr)	2002-06-20
DE60111570D1 (de)	2005-07-21
DK1349856T3 (da)	2005-10-17
UY27069A1 (es)	2002-07-31
NO20032674D0 (no)	2003-06-12
CN1247574C (zh)	2006-03-29
IL156264A0 (en)	2004-01-04
AU2002238415B2 (en)	2007-01-04
ATE297922T1 (de)	2005-07-15
NO325810B1 (no)	2008-07-21
PL366006A1 (en)	2005-01-24
RS50933B (sr)	2010-08-31
ES2243578T3 (es)	2005-12-01
KR100520651B1 (ko)	2005-10-11
YU47703A (sh)	2006-05-25
SK8732003A3 (en)	2004-04-06
JP4021766B2 (ja)	2007-12-12
CZ20031882A3 (cs)	2003-12-17
DE60111570T2 (de)	2006-05-11
MXPA03005170A (es)	2003-09-22
MY136741A (en)	2008-11-28
MA26973A1 (fr)	2004-12-20
SI1349856T1 (en)	2005-10-31
JP2004521095A (ja)	2004-07-15
CY1105587T1 (el)	2010-07-28
EG24358A (en)	2009-03-04
CN1481382A (zh)	2004-03-10
US6482951B2 (en)	2002-11-19
HK1063314A1 (en)	2004-12-24
NZ526236A (en)	2004-12-24
TWI294876B (en)	2008-03-21
HUP0400587A2 (hu)	2004-06-28
NO20032674L (no)	2003-06-12

Publication	Publication Date	Title
EP1349856B1 (fr)	2005-06-15	Activateurs de l'isoindoline-1-one glucokinase
EP1549638B1 (fr)	2007-10-03	Indole-3-carboxamides servant d'activateurs de glucokinase (gk)
AU2002238415A1 (en)	2002-08-29	Isoindolin-1-one glucokinase activators
KR100519826B1 (ko)	2005-10-06	파라-아민 치환된 페닐아미드 글루코키나제 활성화제
EP1282612B1 (fr)	2004-12-29	Activateurs heteroaromatiques de la glucokinase a base d'alkynyle-phenyle
AU2001270494A1 (en)	2002-01-31	Alkynyl phenyl heteroaromatic glucokinase activators
AU2001265914A1 (en)	2002-02-07	Para-amine substituted phenylamide glucokinase activators
HK1083098B (en)	2008-02-22	Indole-3-carboxamides as glucokinase (gk) activators